IL2 and melanoma: Inhibition of melanin production by blocking the catalytic site of tyrosinase or chelating copper ions, sensitizing melanoma cells to the cytotoxic effect of cyclophosphamide, and enhancing the immunotoxicity activity of IL-2-activated lymphocytes are effective targets for the treatment of advanced melanoma [32,191,192].